{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:18:55Z","timestamp":1761920335473,"version":"3.37.3"},"reference-count":34,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1136\/jnnp-2017-316236","type":"journal-article","created":{"date-parts":[[2017,8,27]],"date-time":"2017-08-27T00:20:15Z","timestamp":1503793215000},"page":"1073-1078","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events"],"prefix":"10.1136","volume":"88","author":[{"given":"Massimiliano","family":"Calabrese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-4548","authenticated-orcid":false,"given":"Marco","family":"Pitteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albulena","family":"Bajrami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Castellaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Magliozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,8,26]]},"reference":[{"key":"key-10.1136\/jnnp-2017-316236-1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2017-316236-2","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for multiple sclerosis","volume":"356","author":"Ransohoff","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2017-316236-3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2017-316236-4","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2017-316236-5","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2017-316236-6","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1177\/1352458515607651","article-title":"PML risk stratification using anti-JCV antibody index and L-selectin","volume":"22","author":"Schwab","year":"2016","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2017-316236-7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/00207454.2011.622452","article-title":"Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab","volume":"122","author":"Baumgartner","year":"2012","journal-title":"Int J Neurosci"},{"key":"key-10.1136\/jnnp-2017-316236-8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1212\/01.wnl.0000327341.89587.76","article-title":"Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy","volume":"72","author":"St\u00fcve","year":"2009","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2017-316236-9","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2017-316236-10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","article-title":"Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers","volume":"4","author":"Lo Re","year":"2015","journal-title":"Neurol Ther"},{"key":"key-10.1136\/jnnp-2017-316236-11","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00415-016-8177-1","article-title":"Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients","volume":"263","author":"Iaffaldano","year":"2016","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2017-316236-12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/cns.12282","article-title":"Treatment options to reduce disease activity after natalizumab: paradoxical effects of corticosteroids","volume":"20","author":"Rossi","year":"2014","journal-title":"CNS Neurosci Ther"},{"key":"key-10.1136\/jnnp-2017-316236-13","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00415-011-6019-8","article-title":"Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study","volume":"258","author":"Magraner","year":"2011","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2017-316236-14","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/1352458512464282","article-title":"Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings","volume":"18","author":"Rinaldi","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2017-316236-15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2017-316236-16","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/ane.12082","article-title":"Switching from natalizumab to fingolimod: an observational study","volume":"128","author":"Sempere","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"key-10.1136\/jnnp-2017-316236-17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2017-316236-18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0033-1343796","article-title":"BG-12 in multiple sclerosis","volume":"33","author":"Phillips","year":"2013","journal-title":"Semin Neurol"},{"key":"key-10.1136\/jnnp-2017-316236-19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2017-316236-20","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.111.190132","article-title":"Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the Nrf2 pathway","author":"Scannevin","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.1136\/jnnp-2017-316236-21","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1212\/NXI.0000000000000183","article-title":"Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis","volume":"3","author":"Gross","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"key-10.1136\/jnnp-2017-316236-22","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1212\/NXI.0000000000000076","article-title":"Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate","volume":"2","author":"Spencer","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"key-10.1136\/jnnp-2017-316236-23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/acn3.270","article-title":"Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis","volume":"3","author":"Michell-Robinson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"key-10.1136\/jnnp-2017-316236-24","first-page":"135245851770706","article-title":"Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count","volume":"373","author":"Longbrake","year":"2017","journal-title":"Mult Scler J"},{"key":"key-10.1136\/jnnp-2017-316236-25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2017-316236-26","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med Overseas Ed"},{"key":"key-10.1136\/jnnp-2017-316236-27","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00415-016-8162-8","article-title":"Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors","volume":"263","author":"Zurawski","year":"2016","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2017-316236-28","first-page":"1444","volume-title":"Rating neurologic impairment in multiple sclerosis : An expanded disability status scale (EDSS)","author":"Kurtzke","year":"1983"},{"issue":"Issue 17, Supplement 3","key":"key-10.1136\/jnnp-2017-316236-29","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.0b013e3181dbb51c","article-title":"Freedom from disease activity in multiple sclerosis","volume":"74","author":"Havrdova","year":"2010","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2017-316236-30","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target No evident disease activity (NEDA) in multiple sclerosis?","author":"Giovannoni","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"key-10.1136\/jnnp-2017-316236-31","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2017-316236-32","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/ijd.12834","article-title":"The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis","volume":"54","author":"Tahvili","year":"2015","journal-title":"Int J Dermatol"},{"key":"key-10.1136\/jnnp-2017-316236-33","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1212\/WNL.0000000000000296","article-title":"Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes","volume":"82","author":"Giovannoni","year":"2014","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2017-316236-34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.jid.5700996","article-title":"Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression","volume":"128","author":"Rubant","year":"2008","journal-title":"J Invest Dermatol"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2017-316236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:08:40Z","timestamp":1601057320000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2017-316236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,26]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,11,28]]},"published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1136\/jnnp-2017-316236"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2017-316236","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"type":"print","value":"0022-3050"},{"type":"electronic","value":"1468-330X"}],"subject":[],"published":{"date-parts":[[2017,8,26]]}}}